| 7 | Taxation |
| 2017 | 2016 | 2015 | ||||||||||
| £’000 | £’000 | £’000 | ||||||||||
| Current tax credit | ||||||||||||
| Current tax credited to the income statement | 1,253 | 1,936 | 1,002 | |||||||||
| Taxation payable in respect of foreign subsidiary | - | (25 | ) | - | ||||||||
| 1,253 | 1,911 | 1,002 | ||||||||||
| Deferred tax credit | ||||||||||||
| Reversal of temporary differences (Note 23) | 12 | 7,249 | 131 | |||||||||
| Total tax credit | 1,265 | 9,160 | 1,133 | |||||||||
The reasons for the difference between the actual tax charge for the year and the standard rate of corporation tax in the United Kingdom applied to losses for the year are as follows:
| 2017 | 2016 | 2015 | ||||||||||
| £’000 | £’000 | £’000 | ||||||||||
| Loss before tax | (17,329 | ) | (29,322 | ) | (11,232 | ) | ||||||
| Expected
tax credit based on the standard rate of United Kingdom corporation tax at the domestic rate of 19.25% (2016: 20.25%, 2015:20.25%) |
(3,336 | ) | (5,864 | ) | (2,274 | ) | ||||||
| Expenses not deductible for tax purposes | 412 | 1,022 | 185 | |||||||||
| Adjustments to brought forward values | - | - | (8 | ) | ||||||||
| Additional deduction for R&D expenditure | - | 4 | (789 | ) | ||||||||
| Surrender of tax losses for R&D tax refund | (1,196 | ) | (1,503 | ) | 406 | |||||||
| Reversal of deferred tax on impairment | - | (3,421 | ) | - | ||||||||
| Unrelieved
tax losses and other deductions arising in the period |
(156 | ) | (166 | ) | (78 | ) | ||||||
| Foreign exchange differences | (84 | ) | 712 | - | ||||||||
| Deferred tax not recognised | 3,095 | 491 | 1,425 | |||||||||
| Adjustment in respect of prior years | - | (435 | ) | - | ||||||||
| Total tax credited to the income statement | (1,265 | ) | (9,160 | ) | (1,133 | ) | ||||||
The taxation credit arises on the enhanced research and development tax credits accrued for the respective periods.